Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Hematology

Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling

Diana Ernst, RPh

January 26, 2021

Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.

General Hematology

FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines

Diana Ernst, RPh

January 7, 2021

Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.

Anemia

FDA Requests Clarification of Data to Complete Roxadustat Review

Diana Ernst, RPh

January 5, 2021

The Agency announced that additional clarification of clinical data was needed prior to completing the review.

General Hematology

Orladeyo Now Available for Hereditary Angioedema

Diana Ernst, RPh

December 18, 2020

The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.

General Hematology

ACIP: COVID-19 Vaccine Should Be Offered to HCPs, LTC Residents First

Diana Ernst, RPh

December 3, 2020

The recommendation was made based on the number of confirmed COVID-19 cases among these 2 groups, as well as ethical and scientific considerations.

General Hematology

FDA Authorizes COVID-19 Test That Provides Rapid Results at Home

Diana Ernst, RPh

November 20, 2020

This is the first time the Agency has authorized a COVID-19 diagnostic test that provides rapid results at home.

General Hematology

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective

Diana Ernst, RPh

November 17, 2020

The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.

General Hematology

COVID-19 Vaccine Candidate More Than 90% Effective, Say Pfizer, BioNTech

Diana Ernst, RPh

November 10, 2020

The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.

General Hematology

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

Diana Ernst, RPh

August 26, 2020

The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.

General Hematology

COVID-19 Vaccine Candidate Provides Protection in Animal Challenge Study

Diana Ernst, RPh

August 3, 2020

Vaccination with mRNA-1273, Moderna’s coronavirus disease 2019 (COVID-19) vaccine candidate, led to robust immune responses and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in nonhuman primates.

Next post in General Hematology